In breast cancer, IL-1β is often produced by activated macrophages and dendritic cells in the tumor microenvironment, and it can also be secreted by highly aggressive breast cancer cells, particularly in triple-negative breast cancer, which exhibits aberrant inflammasome activation [14]. Here, IL1B is linked to breast carcinoma.